Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530047 | 1.00 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL530046 | 1.00 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL29243120 | 0.98 | GSR (0.44) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL1010091 | 0.82 | GSR (0.47) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL8778638 | 0.80 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL8778639 | 0.80 | GSR (0.45) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL27263635 | 0.79 | GSR (0.48) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL1537223 | 0.79 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL29075853 | 0.79 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL997560 | 0.79 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585485-A2 | COMPOSITIONS FOR THE REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2004064749-A2 | COMPOSITIONS FOR THE REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2004-08-05 | — | — | WO | claimed |
| US-4851448-A | Gem-dihalo-1,8-diamino-4-aza-octanes | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-07-25 | — | — | US | claimed |
| WO-2018170553-A1 | COMPLEXES AND USES THEREOF | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2018-09-27 | — | — | WO | disclosed |
| CN-102498129-B | Use BV8 antagonist or the transfer of G-CSF antagonist Tumor suppression | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-02 | — | — | CN | disclosed |
| CN-104822681-A | Pyrazolopyrimidine compounds as kinase inhibitors | PRINCIPIA BIOPHARMA INC | 2015-08-05 | — | — | CN | disclosed |
| CN-101765596-B | Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER IP GMBH | 2015-04-29 | — | — | CN | disclosed |
| CN-104487441-A | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for treatment of cancer and autoimmune diseases | PRINCIPIA BIOPHARMA INC | 2015-04-01 | — | — | CN | disclosed |
| EP-2801366-A2 | Improved apo E analogs and methods for their use | Cognosci, Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8288335-B2 | ApoE analogs and methods for their use | Cognosei, Inc. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110306550-A1 | APOE ANALOGS AND METHODS FOR THEIR USE | COGNOSCI, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| CN-101765596-A | Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE AG | 2010-06-30 | — | — | CN | disclosed |
| EP-2099442-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1796708-A4 | IMPROVED APO E ANALOGS AND METHODS FOR THEIR USE | COGNOSCI INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090042783-A1 | APO E ANALOGS AND METHODS FOR THEIR USE | CORNERSTONE BIOSCIENCES, INC. | 2009-02-12 | — | — | US | disclosed |
| WO-2008082856-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1796708-A2 | IMPROVED APO E ANALOGS AND METHODS FOR THEIR USE | Cognosci, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029028-A2 | IMPROVED APO E ANALOGS AND METHODS FOR THEIR USE | COGNOSCI, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-1999049859-A9 | DFMO AND SULINDAC COMBINATION IN CANCER CHEMOPREVENTION | UNIV ARIZONA (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | GSR 557/4885DPP7 3003/4885DPP4 1174/4885 |
| US-20090042783-A1 | APO E ANALOGS AND METHODS FOR THEIR USE | APOB, APOL1, APP | GSR 736/4885DPP7 2185/4885DPP4 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.